• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference

    11/4/24 4:01:00 PM ET
    $TSVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TSVT alert in real time by email

    2seventy bio, Inc. (NASDAQ:TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET.

    Participants can access the financial results conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It's recommended that participants join 10 minutes prior to the event's start.

    Members of the management team will also be presenting at the following upcoming investor conference:

    • Guggenheim's Inaugural Healthcare Innovation Conference in Boston, MA on Wednesday, November 13, 2024 at 10:00 a.m. ET

    A live webcast of the fireside chat will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. Replays will be archived on 2seventy bio's site for 30 days following the event.

    About 2seventy bio

    Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body's immune response to tumor cells and how to translate cell therapies into practice, we're applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our "why" and keeping our people and culture top of mind every day.

    For more information, visit www.2seventybio.com.

    Follow 2seventy bio on social media: X (Twitter) and LinkedIn.

    2seventy bio is a trademark of 2seventy bio, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241104367323/en/

    Get the next $TSVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TSVT

    DatePrice TargetRatingAnalyst
    6/6/2024$5.00 → $2.00Neutral → Sell
    Goldman
    1/31/2024Outperform → Market Perform
    TD Cowen
    1/31/2024$5.00 → $18.00Market Perform → Outperform
    Leerink Partners
    10/30/2023$6.00Outperform → Market Perform
    Leerink Partners
    10/12/2023$13.00Buy
    Citigroup
    9/13/2023$5.00Buy → Neutral
    Goldman
    9/12/2023Buy → Neutral
    Guggenheim
    7/28/2023$25.00 → $13.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TSVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 2seventy bio downgraded by Goldman with a new price target

      Goldman downgraded 2seventy bio from Neutral to Sell and set a new price target of $2.00 from $5.00 previously

      6/6/24 7:21:43 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio downgraded by TD Cowen

      TD Cowen downgraded 2seventy bio from Outperform to Market Perform

      1/31/24 9:14:22 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded 2seventy bio from Market Perform to Outperform and set a new price target of $18.00 from $5.00 previously

      1/31/24 7:24:00 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care